New oral painkiller candidate enters human safety testing
NCT ID NCT07676357
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental drug called RFUS-949, taken as a tablet, to see if it is safe and how it behaves in the body. The study involves 28 healthy Chinese adults aged 18 to 45. Participants receive either the drug or a placebo daily for 6 days, with close monitoring for side effects and blood tests to measure drug levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RFUS-949
What this could lead to
If safe and well-tolerated, this could pave the way for a new oral pain medication.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not people with pain. It only tests safety and drug levels, not whether it actually relieves pain. Many drugs fail at this stage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE AND CHRONIC PAIN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266003, China